An example is the IDH1‐mutant inhibitor ivosidenib (AG‐120), which has been approved by the US Food and Drug Administration for the treatment of refractory acute myeloid leukemia.[21] Recently, wild‐type IDH1 has been shown to play a role in tumor development and progression. The gene discussed is IDH1; the disease is acute myeloid leukemia.